Total Artificial Heart Technology: Where Are We Now?

AbstractPurpose of ReviewThe intended goal of this paper is to review current indications, available devices, and future directions of total artificial heart therapies. Throughout the paper, we sought to help clinicians identify appropriate patients who might be considered for total artificial heart therapy, highlighting the most current data regarding outcomes and adverse events.Recent FindingsThe INTERMACS report on the total artificial heart has recently been published in theJournal of Heart and Lung Transplantation and represents the largest study to date on available TAH therapies. Notable findings include better outcomes at experienced centers, likely a result of appropriate patient selection, timing, and management of device therapy.SummaryThere are multiple new types of total artificial hearts under development. Having learned from prior experience, and with increasing use and standardization of peri- and post-operative management, there is hope of ongoing success in improving care for those with advanced heart disease and biventricular failure with the use of this technology.
Source: Current Transplantation Reports - Category: Transplant Surgery Source Type: research

Related Links:

This study elucidates the potential to use mitochondria from different donors (PAMM) to treat UVR stress and possibly other types of damage or metabolic malfunctions in cells, resulting in not only in-vitro but also ex-vivo applications. Gene Therapy in Mice Alters the Balance of Macrophage Phenotypes to Slow Atherosclerosis Progression Atherosclerosis causes a sizable fraction of all deaths in our species. It is the generation of fatty deposits in blood vessel...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is established therapy for short-term circulatory support for children with life-treating cardiorespiratory dysfunction. In children with congenital heart disease (CHD), ECMO is commonly used to support patients with post-cardiotomy shock or complications including intractable arrhythmias, cardiac arrest, and acute respiratory failure. Cannulation configurations include central, when the right atrium and aorta are utilized in patients with recent sternotomy, or peripheral, when cannulation of the neck or femoral vessels are used in nonoperative patients.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: State of Art Source Type: research
Researchers at the University of Bristol have developed a way to make stem cells move toward heart tissue when they are injected intravenously. The treatment could improve the efficacy of stem cell therapies for heart disease, which are currently ham...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiac Surgery Cardiology Genetics Rehab Source Type: blogs
In this study, we determine whether transient reintroduction of embryonic stem cell cycle miR-294 promotes cardiomyocyte cell cycle reentry enhancing cardiac repair after myocardial injury. A doxycycline-inducible AAV9-miR-294 vector was delivered to mice for activating miR-294 in myocytes for 14 days continuously after myocardial infarction. miR-294-treated mice significantly improved left ventricular functions together with decreased infarct size and apoptosis 8 weeks after MI. Myocyte cell cycle reentry increased in miR-294 hearts parallel to increased small myocyte number in the heart. Isolated adult myocytes from miR-...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
The European Pediatric PVD Network (EPPVDN) is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia (BPD), PH associated with congenital heart disease (CHD), persistent PH of the newborn (PPHN), and related cardiac dysfunction. The executive writing group (EWG) members conducted searches of the PubMed/MEDLINE bibliographic database (1990-2018), held face-to-face and web-based meetings.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research
Publication date: Available online 8 June 2019Source: Revista Española de Cardiología (English Edition)Author(s): María Lozano-Balseiro, Isaac Martínez-Bendayán, Oscar Pato-López, Mercedes De la Torre-Bravos, Francis Fynn-Thompson, Víctor Bautista-Hernández
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
In this study, a significant (30%) increase in maximum lifespan of mice was found after nonablative transplantation of 100 million nucleated bone marrow (BM) cells from young donors, initiated at the age that is equivalent to 75 years for humans. Moreover, rejuvenation was accompanied by a high degree of BM chimerism for the nonablative approach. Six months after the transplantation, 28% of recipients' BM cells were of donor origin. The relatively high chimerism efficiency that we found is most likely due to the advanced age of our recipients having a depleted BM pool. In addition to the higher incorporation rates, ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This study shows that mRNA levels of the aging related lamin A splice variant progerin, associated with premature aging in HGPS, were significantly upregulated in subjects with BMI ≥ 25 kg/m2. Moreover, our data revealed a significantly positive correlation of BMI with progerin mRNA. These data provide to our knowledge for the first-time evidence for a possible involvement of progerin in previously observed accelerated aging of overweight and obese individuals potentially limiting their longevity. Our results also showed that progerin mRNA was positively correlated with C-reactive protein (CRP). This might suggest an as...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Cytomegalovirus (CMV) is a betaherpesvirus, the impacts of which are well known to clinicians providing post-transplant cystic fibrosis care. Lung transplant recipients have the highest risk of any solid-organ transplant for CMV reactivation and ganciclovir resistance [1, 2]. Furthermore, CMV reactivation increases the risk of chronic lung allograft dysfunction. However, even in general populations, CMV seropositivity is associated with adverse outcomes including cognitive impairment, frailty, heart disease and all-cause mortality [3–5]. How CMV may contribute to disease is not evident but many streams of evidence su...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research
Geng-Hong Xia1†, Chao You1,2†, Xu-Xuan Gao1, Xiu-Li Zeng1, Jia-Jia Zhu1, Kai-Yu Xu3, Chu-Hong Tan1, Ruo-Ting Xu1, Qi-Heng Wu1, Hong-Wei Zhou3, Yan He4*‡ and Jia Yin1*‡ 1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China 2Department of Neurology, The First People's Hospital of Zunyi, Zunyi, China 3State Key Laboratory of Organ Failure Research, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China 4Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical Univ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Cardiology | Heart | Heart Disease | Heart Transplant | Lung Transplant | Study | Transplants